glp-1 gip dual agonist The Emerging Role of and Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction Curious about the latest in

Effects of GLP-1 and Other Gut Hormone Receptors on the Gastrointestinal Tract and Implications in Clinical Practice

See related commentary by McIntyre B ipolar disorder (BD) and major depressive disorder (MDD) affect 7 million and 21 million adults in the US, respectively

L., Bhatta, M., et al

The study provides important insights for clinical practice and future research

In a small-scale four-week long, open-label study involving 14 individuals diagnosed with major depressive disorder and bipolar disorder, which also displayed impaired executive function, treatment with liraglutide significantly reduced Hamilton Depression Rating Scale (HDRS) scores and improved executive function, however, at the same time it did not improve cognitive function in patients [122]

Additional Resources Mercer: GLP-1 Considerations for 2026 Peterson-KFF: Employer Perspectives on GLP-1 Coverage Costs Blue Cross Blue Shield: How GLP-1s Could Increase Employer Premiums Morgan Lewis: GLP-1 Coverage, Obesity, and the ADA Related: ERISA Voluntary Benefits Compliance Checklist for Brokers (BenefitFlow) Sources for statistics cited in this article include SHRM, EBRI, HUB International, KFF, Mercer, Blue Cross Blue Shield Association, and the Business Group on Health